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Abstract 
Myeloid derived suppressor cells (MDSCs) are heterogeneous subsets of 
immune cells and they function to inhibit host T cells activation leading 
to tumour growth. Currently, the majority of studies support key 
contributions of MDSCs to tumour progression via direct mechanisms 
immune mediated and indirect mechanism which is not directly 
associated with immune suppression. Due to the complexity of MDSCs 
heterogeneity, the aspect of MDSCs phenotype, morphology and function 
is poorly investigated up to date. And for this reason, this review will 
provide a comprehensive understanding of the role and function of 
MDSCs in cancer patients. Targeting the immunosuppressive cells 
MDSCs may improve the efficacy of immunotherapy in cancer patients in 
future. 
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Abbreviations 
Antigen presenting cells: APCs  
Arginase 1:ARG1 
Bacillus Calmette–Guérin: BCG 
Colorectal cancer: CRC 
Cyclooxygenase 2: COX-2  
Dendritic cells: DCs 




Inducible nitric oxide: iNOS 
Myeloid-derived suppressive cells: MDSCs 
Monocytic Myeloid-derived suppressive cells: M-MDSCs  
Natural killer cells: NK 
Nuclear factor kappa β: NF-kβ 
Reactive oxygen species: ROS 
Prostaglandin E2: PGE2  
World Health Organisation: WHO 
Tumour infiltrating lymphocytes: TILs 
T regulatory cells: Treg cells  
Tumour-associated antigens: TAA 
Transforming growth factor beta: TGF-β  
T regulatory cells: Treg 
Tumour microenvironment: TME 
Signal transducer and activator of transcription: STAT 
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1. Introduction  
Cancer is the second leading cause of deaths worldwide with 9.6 
million deaths in 2018, it is estimated about 1 in 6 deaths of cancer 
patients, according to the latest report from the WHO. Cancer treatment 
by surgery, radiotherapy and chemotherapy, alone or in combination with 
other drugs, have been effective at treating the primary stage of the cancer 
but with severe side effects as failed to control and reduce cancer spread 
(metastasis) (Couzin-Frankel, 2013). Moreover, new cancer therapy 
became urgently needed and scientists currently directed the focus of 
research into understanding the mechanism of the tumourgenesis and the 
mechanism of immune system . 
To understand the immune system, the immune system works 
basically by distinguishing self from non-self-antigens, and it has the 
ability to detect and eliminate any foreign antigens. The immune system 
continuously failed to identify, destroy and eradicate the transformed cells 
during tumour progression in cancer patients, however, tumour 
infiltrating lymphocytes (TILs) (de Lima et al., 2020) and antigen 
presenting cells (APCs) are shown to be non-functional within tumour 
tissue samples, decreased number of mature dendritic cells (DCs) in the 
peripheral blood of cancer patients for further information please refer to 
review (Kumar, Patel, Tcyganov, & Gabrilovich, 2016; Marvel & 
Gabrilovich, 2015). A study reported that the antigen-specific CD4+ T 
cells were rendered unresponsive by the tumours growth, suggesting that 
the T cells function can also be inhibited by cancer cells (Cuenca et al., 
2003) . 
Tumours can induce immunosuppression by the release of 
microvesicles or exosomes (which are found in the body fluids of cancer 
patients of melanoma and colorectal cancer (CRC)). The release of 
microvesicles can promote monocytes and myeloid derived-suppressive 
cells (MDSCs) differentiations and thus support tumours escape the 
immune system recognition (Valenti et al., 2007) . 
However, a new treatment for cancer known as (immunotherapy) 
has been developed in recent years. Immunotherapy works to boost the 
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cells and ultimately improve the survival rate of cancer patients (Sun et 
al., 2019). In contrast to immunotherapy, cancer vaccines are also 
considered as the latest application of active immunotherapy in cancer 
prevention or may cancer treatment (Aly, 2012; Rosenberg, Yang, & 
Restifo, 2004). Cancer vaccine is to degrade and process tumour antigens 
by APCs and then sample it via self-antigens known as major 
histocompatibility complex (MHC) class one (I) and/or class two (II) to T 
cells which then induce an endogenous, long-lasting tumour antigen-
specific immune response by T cells (Couzin-Frankel, 2013; Schuster, 
Nechansky, & Kircheis, 2006). The efficacy of vaccines are usually 
boosted with the combination of adjuvant such as Bacillus Calmette–
Guérin (BCG), interleukein two or twelve (IL-2 or IL-12) in order to 
maintain cellular as well as humoral  immune responses (Habal et al., 
2001; Villinger, 2003) . 
On the other hand, immunotherapy has been successfully used in 
clinical trials to treat a variety of tumours such of these 
immunotherapeutic treatment cytokines, IL-2 and interferon alpha (IFN-
α), which were clinically approved and used for treatment of Kaposi’s 
sarcoma and leukaemia (Hurley & Chapman, 2005; J. C. Yang et al., 
2003). In addition to that, monoclonal antibodies (mAb) based 
immunotherapy such as Rituximab, Cetuximab and Trastuzumab were 
tested for the treatment of leukaemia, non-Hodgkin’s lymphoma, breast 
and CRC (Couzin-Frankel, 2013; Schuster et al., 2006) . 
Furthermore, adoptive cell therapy (ACT – using autologous TILs) 
has been used as the most effective immunotherapy treatment for 
metastatic patients, particularly melanoma, and showed approximately 
50% of tumour regression in cancer patients. The successful use of ACT 
in melanoma patients has opened new opportunities to patients with 
different cancer types and is a promising as new approach to cancer 
treatment (Rosenberg, Restifo, Yang, Morgan, & Dudley, 2008) . 
Despite these developments strategy in immunotherapy, the 
potential effectiveness of cancer immunotherapy has been minimised by 
the immune system particularly by the function of T regulatory cells 
(Tregs) and MDSCs. MDSCs are phenotypically and functionally 
heterogeneous subsets of immune cells (as discussed in subsequent 
sections) and they function to inhibit host T cell activity against tumour 
associated-antigens (TAA) and as a result this will a) minimise the action 
of anticancer immunotherapeutic approaches, b) inhibiting T cells 
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activation and c) leading to tumour growth (Kumar, Patel, et al., 2016; 
Nagaraj et al., 2007). Targeting the immunosuppressive cells; Tregs and 
MDSCs may improve the efficacy of immunotherapy in cancer patients \. 
Taken together, the aspect of MDSCs is poorly investigated and for this 
reason this review will focus on MDSCs and provide a comprehensive 
understanding of their roles in cancer patients. 
2. Definition of MDSCs 
MDSC cells were first described in association with cancer 
development and progression for more than thirty years (Ostrand-
Rosenberg & Sinha, 2009). MDSCs represent the majority of immature 
and haematopoietic immune cells but with various cell subsets, 
physiological, functional and pathological roles (Damuzzo et al., 2015; 
Gabrilovich, Ostrand-Rosenberg, & Bronte, 2012; Khaled, Ammori, & 
Elkord, 2013). Immature myeloid cells are produced in the bone marrow 
from common myeloid progenitor cells and differentiate in order to 
become mature cells into the three functional myeloid subsets; 
macrophages (MΦ), dendritic cells (DCs) and granulocytes (with no 
systemic immunosuppressive effects) in normal individuals (Gabrilovich, 
2017). During pathological conditions, immature myeloid cells are also 
produced but they functionally  differ in comparisons to that produced in 
normal conditions, with an expansion in their immunosuppressive activity 
such as production reactive oxygen species (ROS), nitric oxide (NO), and 
anti-inflammatory cytokines (Condamine, Mastio, & Gabrilovich, 2015; 
Youn, Collazo, Shalova, Biswas, & Gabrilovich, 2012). Studies reported 
that the accumulation of MDSCs implicated in inflammation and tumours 
(Bunt, Sinha, Clements, Leips, & Ostrand-Rosenberg, 2006; Capietto et 
al., 2013; Ostrand-Rosenberg & Sinha, 2009; Porembka et al., 2012).  
2.1. MDSCs characterisation in Mice and Humans 
MDSCs in mice and humans are defined as a mixture of activated 
immature myeloid cells; granulocytic or polymorphonuclear (PMN) and 
monocytic or mononuclear cells, which can be identified by the 
expression of cell surface markers (Damuzzo et al., 2015) as discussed in 
more details in subsequent sections. 
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MDSCs in mice are identified by the co-expression of the myeloid 
differentiation antigen (Gr-1) and cluster differentiation (CD11b) (Youn 
et al., 2012). Gr-1 consists of two epitopes: Ly-6G and Ly-6C, the level of 
Ly-6C epitopes distinguish the granulocytic (G-MDSCs) and monocytic 
(M-MDSCs) phenotypic. MDSCs express CD11b Ly-6G and Ly-6C, in 
particular, G-MDSCs cells express CD11b+ Ly-6G+ and Ly-6Clow, 
whereas M-MDSCs express CD11b+ Ly-6G and Ly-6Chigh (Movahedi et 
al., 2008; Movahedi et al., 2010; R. Yang et al., 2006; Youn et al., 2012). 
The phenotypical features of the G-MDSCs and M-MDSCs subsets are 
most often are associated with population of immature myeloid cells, 
share structural, but they differ in functional activity and their exact roles 
in pathological conditions remain elusive. However, several reports 
indicated that they implicated in cancer and autoimmune diseases (Cripps 
& Gorham, 2011; Greten, Manns, & Korangy, 2011; Nagaraj et al., 2009; 
Zhao, Wu, Shao, Shi, & Zhao, 2015). In tumour models, it was shown 
that G- and M-MDSC subpopulations were expanded with greater 
expansion of the G-MDSC population than M-MDSC population 
(Gabrilovich & Nagaraj, 2009; Zhou et al., 2010). In most tumour-bearing 
mice, the G-MDSC subsets increase in parallel with the increase of M-
MDSCs population in limited tumour models (Youn, Nagaraj, Collazo, & 
Gabrilovich, 2008). Other findings reported that the expansion of MDSCs 
is not associated with their suppressive role but it is linked to their 
function activity within the tumour environment (Gabrilovich, Ciernik, & 
Carbone, 1996). A study reported that STAT3 inhibition in tumour-
bearing mice led to MDSC depletion in spleens but not in tumours 
(Kumar, Cheng, et al., 2016). Scientists attempted to characterise the 
nature of the G- and M-MDSCs in mice tumour model, and studies 
demonstrated that the phenotype and cell markers of G-MDSCs are 
relatively similar to normal mature neutrophils, but their functional 
activity are different (Damuzzo et al., 2015; Fridlender et al., 2012; Youn 
et al., 2012).  
2.3. MDSCs in Human 
The phenotype of human MDSCs is defined as suppressive 
monocyte that contains membrane cell marker CD14 (Mielcarek, Martin, 
& Torok-Storb, 1997; J. Talmadge et al., 1996). Later on, human MDSCs 
from head and neck cancer patients were described to co-express CD34 
and these MDSCs were defined as haematopoietic progenitor cells as they 
were negative for the expression CD3, CD19, CD56 and CD13. Further 
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investigations were performed and identified the phenotypic expression of 
human MDSCs as characterised with the absence of human leukocyte 
antigen D-related (HLA-DR) expression and one or both myeloid marker 
(CD33 or CD11b) and reviewed (J. E. Talmadge & Gabrilovich, 2013).  
Given the history of MDSCs, human MDSCs in cancer patients were 
initially defined as CD11b+, CD33+, CD14- and HLA-DR- (J. E. 
Talmadge & Gabrilovich, 2013). Because of the heterogeneity of MDSCs 
subset, the identification of human G- and M-MDSCs population have 
been challenging and thus were examined in different types of human 
cancers (Lechner et al., 2011; Nagaraj et al., 2010). For example, studies 
in renal cell carcinoma (RCC) found that G-MDSCs express CD15, whilst 
M-MDSCs subsets were positive for CD14 expression (Ko et al., 2009; 
Poschke, Mougiakakos, Hansson, Masucci, & Kiessling, 2010; Rodriguez 
et al., 2009).  
Taken together, this suggests that the MDSCs subsets may express 
several surface molecules that assist in differentiation, and 
immunosuppressive activity function of MDSCs. Further investigations 
should be performed to understand the role, function and the 
characteristics cell surface markers of MDSCs subsets in the tumour 
microenvironment (TME).   
2.4. MDSC Expansion and activation in cancer 
The majority of studies from tumour bearing mice and human 
cancers reported that the induction and expansion of MDSCs in cancer 
environment is mediated by multiple factors including cytokines, growth 
factors and pro-inflammatory molecules (Serafini, Borrello, & Bronte, 
2006; Umansky, Blattner, Gebhardt, & Utikal, 2016). The potential 
implicated factors in human cancers are divided into two groups: the first 
group: MDSC expansion promoting factors and the second group MDSC 
activating factors (Gabrilovich & Nagaraj, 2009). The MDSCs expansion 
is facilitated by triggering a signalling cascades that regulate proliferation, 
differentiation, cell survival and cell death via Janus tyrosine kinase 
(JAK) protein family members and signal transducer and activator of 
transcription 3 (STAT3) (Gabrilovich & Nagaraj, 2009; Zhang et al., 
2010). In particular, a study showed that STAT3 is the main transcription 
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endothelial growth factor (VEGF) were associated with down-regulation 
of the activated STAT3 and ROS production in MDSC (Jayaraman et al., 
2012). These evidence indicated that the mechanism that involved via the 
modulation of tumour VEGF secretion and upregulation of STAT3 and 
ROS in MDSC (Qu, Yan, Blum, Kapur, & Du, 2011; Wu, Du, Li, Qu, & 
Yan, 2011). A study demonstrated that in ovarian cnacer VEGF 
expression induced MDSCs leading to the inhibition of local immunity 
and poor cancer prognosis (Horikawa et al., 2017).  
However, it was reported that downstream of STAT3 may regulate 
MDSCs expansion by S100A8 and S100A9 proteins induction (Cheng et 
al., 2008). The mentioned proteins are calcium-binding proteins that are 
released in response to cell damage and have been shown involved in the 
production of ROS and accumulation MDSCs, particularly G-MDSCs 
(Dufait et al., 2016; Turovskaya et al., 2008). In addition, it reported that 
activating factors also plays a critical role on MDSC expansion through 
multiple signalling pathways including STAT6, STAT1, and nuclear 
factor-κB (NF-κB) (Gabrilovich & Nagaraj, 2009). STAT1 is the major 
transcription factor that activated by IFN-γ. STAT1 is mainly responsible 
for upregulation of Arginase (ARG1) and inducible nitric oxide synthase 
(iNOS) in MDSCs within the tumour microenvironment (Gabrilovich & 
Nagaraj, 2009). 
2.5. Mechanisms of MDSC in cancer:  
The impact of MDSCs on cancer induction, expansion and including 
tumour angiogenesis and metastasis (Dysthe & Parihar, 2020), which is 
better described as two staged effects; the first stage is involved an 
abnormal myelopoiesis and recruitment of MDSCs into the tumour tissue. 
The second stage is an active MDSC cytokine production within the 
environment resulting in progression of cancer (Gabrilovich et al., 2012).  
MDSCs mediate their tumour induced immunosuppression via a variety 
of potential mechanisms (Wang, Ding, Guo, & Wang, 2019). MDSCs 
mediate their T cells suppression in cancer through mainly two ways a) 
the direct cell contact with immune cells and b) through the effects of 
soluble mediators such as ARG1, iNOS, ROS, cyclooxygenase 2 (COX-
2), prostaglandin E2 (PGE2), transforming growth factor beta (TGF-β), 
Treg cells and IL-10 (Bogdan, 2010; Condamine & Gabrilovich, 2011; 
Elliott, Doherty, Sheahan, & Ryan, 2017; Srivastava, Sinha, Clements, 
An update review on immunosuppressive cells; Myeloid derived suppressor cells 
(MDSCs) in cancers 
 
66 
   العلوم األساسية والتطبيقية: مجلة الجامعة األسمرية
Journal of Alasmarya University: Basic and Applied Sciences 
Rodriguez, & Ostrand-Rosenberg, 2010). The mechanism of action of 
these mediators are presented briefly in the following sections.  
2.5.1 ARG1, iNOS and ROS 
L-arginine metabolism has been recognised as a major key player in 
the suppressive activity. ARG1 and iNOS are expressed at high level in 
MDSCs and they utilise the L-arginine to produce urea and nitrogen 
(NO), and they are associated with an inhibition of T cells proliferation 
(by decreasing T cell receptors expression) (Bogdan, 2010; Raber et al., 
2014; Rodriguez et al., 2009). Moreover, it has been shown that MDSCs 
inhibit T cells activation by degrading amino acid (cysteins) that is 
essential for T cells activation (Srivastava et al., 2010).  
On the other hand, ROS production has been reported to be a major 
regulator of the suppressive activity of the G-MDSCs in both mice and 
human cancer (Qu, Boelte, & Lin, 2012).  
2.5.2 PGE2 and COX-2 
PGE2 and COX-2 are both potent mediators produced during 
inflammatory conditions and by many tumour cells as well. PGE2 were 
the main receptors found in human MDSCs (Fujita et al., 2011; Rodriguez 
et al., 2005). PGE2 functions to upregulate ARG1 and regulate MDSC 
and recruitment of T cell immune suppression (Fujita et al., 2011; 
Obermajer & Kalinski, 2012a, 2012b; Obermajer et al., 2012; Sinha, 
Clements, Fulton, & Ostrand-Rosenberg, 2007). A study demonstrated 
that PGE2-regulated accumulation of MDSCs and this contributes to the 
recovery of NK cells activity in vitro (Mao et al., 2014). In contrast to 
PGE2, COX-2 was over expressed in a number of human tumours 
including lung, colon, breast and prostate cancers (Nagaraj et al., 2010). 
2.5.3 TGF-β 
TGF-β is a multifunctional cytokine that associated with MDSCs 
and tumour growth, reviewed largely by (Letterio & Roberts, 1998). It 
has been demonstrated that patients with squamous cell carcinoma of the 
head and neck (SCCHN), their MDSC subset (CD14+HLA-DR- MDSC) 
were high numbers and produced higher levels of TGF-β than other 
MDSC subsets (Chikamatsu et al., 2012). Other studies demonstrated that 
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with anti-CD86 and anti-PD-L1 lead to T-cell proliferation and the 
secretion of IFN-γ. These evidence likely indicate that MDSC is able to 
produce TGF-β which likely has immunosuppressive effects as well as 
promotes tumour growth (Lu et al., 2011; Park & Lee, 2017).    
2.5.4 Treg cells 
The available data indicate that MDSCs are involved in Treg cells 
differentiation in various pathways. Huang and colleagues reported that 
the induction of Treg cells by MDSCs was IFN-γ dependent in the 
presence of IL-10 and antigen-associated activation of tumour-specific T 
cells (Huang et al., 2006). In mice model, a study demonstrated that 
tumour-infiltrating MDSCs express high levels of chemokines receptors 
CCR5 and cognate ligands CCL3, CCL4, and CCL5. When tumour tissue 
of mice were injected with CCL4 and CCL5, tumour-infiltrating Treg 
cells were increased (Lee et al., 2016; Schlecker et al., 2012).  
Moreover, another study showed that CCL5 was preferentially 
expressed on CD4+ Foxp3+ Tregs in human pancreatic cancer and 
MDSCs recruit Treg cells into the tumour microenvironment in murine 
model of pancreatic cancer (Tan et al., 2009). In a mouse model of 
lymphoma, it was found that MDSCs induced Treg cells expansion 
through ARG1 pathway and presentation of tumour associated antigens 
(Bronte & Zanovello, 2005; Park & Lee, 2017). Therefore, further 
investigation is mandatory fill the gap of knowledge regarding the cellular 
interactions between Treg cells and MDSCs in cancer.   
3. Conclusion  
MDSC have been reported to be a key player in tumour associated 
immune evasion and it is characterised by a heterogeneous population of 
immature cells. Their accumulation has been reported and associated with 
the development of some human cancers, while their elimination have 
proven to enhance cancer immunotherapy in human cancers. However, 
there remain many questions to be answered, MDSCs phenotypic 
characterisation in different human cancers? What the exact mechanism 
of MDSCs in human cancers? How MDSCs mediate an antigen-specific 
T cell suppression? All these questions needs further investigations. This 
of course will help in future clinical trials which may improve immune-
based therapeutic strategies modulation of MDSCs in cancers. 
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المشتفة و)المثبطة مراجعه حديثه على الخاليا المثبطة للمناعة: الخاليا 
 في السرطانات (من النخاع
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 الملخص
هي عبارة عن مجموعات فرعية ( النخاعالمشتقة من )ن الخاليا المثبطة للمناعة إ
غير متجانسة من الخاليا المناعية وتعمل على تثبيط تنشيط الخاليا التائية للعائل 
 ذيالحاليا، معظم الدراسات تدعم الدور الرئيسي . مما يؤدي الى نمو السرطان
 لنمو السرطان عن طريق االليات المباشرة بواسطة للمناعةتلعبه الخاليا المثبطة 
ليات الغير مباشرة التي الترتبط مباشرة بتثبيط الجهاز الجهاز المناعي واآل
المناعي. نظرا لتعقيد التركيبه الغير متجانسة للخاليا المثبطة للمناعة فان النمط 
ن. ولهذا السبب، للدراسة حتى اآليفتقر  لهذه الخاليا والوظيفيالظاهري والشكلي 
شامال لدور ووظيفة الخاليا المثبطة للمناعة هذه الدراسة ستوفر مراجعه وفهما 
 المشتقة من النخاع في مرضى السرطان. قد يؤدي فهم واستهداف الخاليا المثبطة
 .تحسين فعالية العالج المناعي في مرضى السرطان في المستقبل إلى للمناعة
